Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
This piece explains typical timelines and triggers for index rule updates, helping you anticipate changes and align investment decisions with the latest rules.
11,819 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
The Supreme Court invalidated President Trump's global tariffs in a 6-3 decision. He vows to impose new duties under ...
New Mexico moves to examine decades of coerced sterilizations in Native communities, with findings due by 2027. The i...
When a bank’s CEO retiires and a director sells shares, investors take notice. This article breaks down what that mov...
As ICE activity rises in 2026, HR teams rely on three critical documents that decide what they may or must not do dur...
Investors ask if Apple stock should be bought before April 30. This guide offers a clear framework, real-world exampl...
When a fintech stalwart like Fiserv experiences a pullback, it can ripple through the broader market. This guide expl...
A new ranking identifies the most expensive states financially for retirees, revealing where housing, healthcare, and...
Palantir has been one of the most debated names in AI-driven analytics. This deep dive weighs the upside against the ...
A fresh industry study finds that a large share of firms cannot locate all their data as AI tools become part of dail...
Structure Therapeutics stock has surged after a major hedge fund increased its stake. This article breaks down what s...
A new ElevenLabs case study shows better.com’s Betsy AI voice agent slashing origination costs by 41% in 2025 while l...